At the Precision Medicine World Conference, Invitae executives noted that early experience in the genetic screening pilot found more people received positive results than previously expected.
The agency is excluding certain advanced diagnostic lab tests and molecular pathology tests from a billing regulation that created administrative headaches for many labs.
The company's recent experience demonstrates the impasse between genetic test developers and payors about the types of clinical evidence needed for coverage.
